Trials / Completed
CompletedNCT02678000
Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function
A Two Part Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Renal Safety, Tolerability and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function on Angiotensin Receptor Blockers
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 84 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 40 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This was a randomized, double-blind, parallel group, placebo-controlled study, in two sequential parts that evaluated the renal safety, tolerability and pharmacokinetics of LHW090 in patients with moderately impaired renal function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LHW090 | LHW090 is orally administered |
| DRUG | Placebo | Matching placebo of LHW090 |
Timeline
- Start date
- 2017-03-10
- Primary completion
- 2018-10-11
- Completion
- 2018-10-11
- First posted
- 2016-02-09
- Last updated
- 2021-10-06
- Results posted
- 2020-02-05
Locations
12 sites across 2 countries: United States, Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02678000. Inclusion in this directory is not an endorsement.